

---

Oliver Gassmann • Alexander Schuhmacher  
Max von Zedtwitz • Gerrit Reepmeyer

# Leading Pharmaceutical Innovation

How to Win the Life Science Race

Third Edition



**Springer**

---

# Contents

<b>1</b>	<b>Innovation: Key to Success in the Pharmaceutical Industry . . . . .</b>	<b>1</b>
1.1	The Productivity Paradox . . . . .	1
1.2	The Blockbuster Imperative . . . . .	8
	Entering the Market Quickly . . . . .	12
1.3	High Risks in Drug Development . . . . .	14
	Differentiation via Clinical Profiles . . . . .	15
1.4	Outlook . . . . .	16
<b>2</b>	<b>The Industry Challenge: Who Would Want to Be in This Business? . . . . .</b>	<b>17</b>
2.1	A Highly Complex Industry . . . . .	17
	Industry Classification and Background . . . . .	18
	Extensive Product Groups . . . . .	18
2.2	Five Forces Analysis of the Drug Industry . . . . .	20
	Force 1: Bargaining Power of Suppliers . . . . .	20
	Force 2: Bargaining Power of Buyers . . . . .	22
	Force 3: Risk of Entry from Potential Competitors . . . . .	23
	Force 4: Threat of Substitute Products . . . . .	24
	Force 5: Rivalry Among Established Companies . . . . .	25
	Force 6: The Regulators . . . . .	26
2.3	Pressure on the Traditional Pharma Business Model . . . . .	28
	Continued Rise of Generics/Branded Generics Products . . . . .	28
	Relevance of Specialty Pharma Drugs . . . . .	29
	Pressure on Portfolio Optimization . . . . .	30
	Increasingly Competitive Marketing Efforts . . . . .	30
	Legal Challenges . . . . .	32
2.4	Growth Drivers for the Years to Come . . . . .	33
2.5	Seeking Salvation in M&A and Diversification . . . . .	36
	Case in Point: Mergermania Around Actavis/Allergan . . . . .	36
	Motivations for Pharma M&A . . . . .	37
	Growth Through Diversification . . . . .	38
2.6	Conclusions . . . . .	39

<b>3</b>	<b>The Science and Technology Challenge: How to Find New Drugs . . .</b>	<b>41</b>
3.1	Rise of the Biotechnology Industry: Boosting Innovation . . . . .	41
3.2	The Challenge of Target Discovery . . . . .	46
3.3	High-Throughput Screening: Fail Earlier, Succeed Sooner . . . . .	48
	Combinatorial Chemistry: Cut Experimental Cycle Times . . . . .	50
	Hit and Lead Generation Technologies Beyond HTS . . . . .	50
3.4	The Bioinformatics and eHealthcare Revolution . . . . .	52
	“Big Data“ and Its Relevance for Pharmaceutical R&D . . . . .	54
3.5	Proteomics and the ‘-omics’ World . . . . .	55
3.6	Pharmacogenetics and Pharmacogenomics . . . . .	56
3.7	Computer-Based Drug Discovery . . . . .	59
3.8	Conclusions . . . . .	61
<b>4</b>	<b>The Pipeline Challenge: How to Organize Innovation . . . . .</b>	<b>63</b>
4.1	The Relevance of Pipeline Management . . . . .	63
	Complexity and Phases of the R&D Process . . . . .	64
4.2	Phases and Checkpoints in the Pharma R&D Process . . . . .	67
	Case-in-Point: Risk Assessment of a Drug Candidate: Pantoprazole . . . . .	68
	Stage-Gate and Portfolio Management . . . . .	70
4.3	Portfolio Analysis . . . . .	71
	Application of a Financial Evaluation of a Project: The Case of Biotech . . . . .	73
4.4	Portfolio Management . . . . .	75
	Portfolio Decision-Making at Merck Serono S.A. . . . .	76
4.5	Conclusions . . . . .	77
<b>5</b>	<b>The Make-or-Buy Challenge: How to In- and Outsource Innovation . . . . .</b>	<b>79</b>
5.1	The Disaggregation of the Pharma Value Chain . . . . .	79
5.2	Outsourcing of Pharmaceutical R&D . . . . .	82
	Outsourcing Strategy: Captive Offshoring at ALTANA Pharma . . .	83
	Contract Research Organizations (CROs) . . . . .	85
5.3	Strategic Research Partnerships . . . . .	88
5.4	In-licensing: Enhancing the Innovation Pipeline . . . . .	91
5.5	Co-development: Benefiting from Joint Resources . . . . .	93
5.6	Out-licensing: Commercializing Internal Research Results . . . . .	96
	Out-Licensing: The Hidden Success Factor . . . . .	96
	The Potential of Out-Licensing . . . . .	97
	Managing Out-Licensing at Novartis . . . . .	100
	Structure of an Out-Licensing Collaboration: The Speedel Case . . .	103
5.7	How to Commercialize a Breakthrough Technology . . . . .	105
	The Soft Capsule Market . . . . .	106
	The InnoGel Technology . . . . .	106
	The Commercialization Process . . . . .	107
	Lessons Learned . . . . .	110
5.8	Conclusions . . . . .	110

<b>6</b>	<b>The Open Innovation Challenge: How to Partner for Innovation . . .</b>	<b>111</b>
6.1	From Closed to Open Pharma . . . . .	111
6.2	Dealing with Uncertainty in Virtual Organizations . . . . .	112
	People at the Center of Dealing with New Forms of Innovation . . .	112
	“Virtual” R&D as a Form of Flexible Engagement . . . . .	114
	Virtual Pharmaceutical R&D Organizations . . . . .	116
6.3	Crowdsourcing: Access the Wisdom of Masses . . . . .	121
6.4	Open Source Drug Discovery . . . . .	124
6.5	Private-Public Partnerships . . . . .	124
6.6	Life-Science Innovation Centers . . . . .	125
6.7	Rising Importance of Venture Funds . . . . .	127
6.8	Managing Intellectual Property Rights . . . . .	129
6.9	Conclusions . . . . .	132
<b>7</b>	<b>The Internationalization Challenge: Where to Access Innovation . . .</b>	<b>135</b>
7.1	Trends in R&D Internationalization . . . . .	135
	Drivers and Barriers to R&D Internationalization . . . . .	136
	Locations of Pharmaceutical R&D Around the World . . . . .	138
	Examples of Global Pharma R&D: Novartis, Chugai, Ferring . . .	140
7.2	New Opportunities for Drug Development in China . . . . .	142
	The Healthcare Context in China . . . . .	142
	Chinese Pharma . . . . .	143
	Foreign Pharma in China . . . . .	146
7.3	Reverse Innovation in Healthcare . . . . .	151
7.4	Conclusions . . . . .	152
<b>8</b>	<b>Future Directions and Trends . . . . .</b>	<b>155</b>
8.1	Three Levels of Future Change . . . . .	155
8.2	Level 1: Increasing R&D Efficiency and Effectiveness . . . . .	156
	Opening Up the Innovation Process . . . . .	156
	More Focus on Commercialization Along the Value Chain . . . .	156
	New Discovery Technologies to Leverage the Potential of Personalized Medicine . . . . .	156
	New Biologics to Capture the Full Growth Potential . . . . .	157
	New Drug Technologies to Provide New Blockbuster Drugs . . . .	157
	Integrated Solutions to Treat Complex Diseases . . . . .	157
	Replacing Disease-Centered Approach with Systematic Early Discovery . . . . .	158
	Reducing Serendipity in Discovery by Balancing Data Generation and Data Analysis Tools . . . . .	158
	Focusing on Complexity and Diversity in Compound Libraries . . .	158
8.3	Level 2: Redefining the Business Model . . . . .	159
	Finding the ‘Sweet Spot’ in the Pharmaceutical Value Chain . . . .	159
	Becoming a Knowledge “Leverager” . . . . .	159
	Developing Downstream Capabilities Within R&D . . . . .	159

---

	Exploiting the Potential of Emerging Markets . . . . .	160
	Strategies for How to Benefit from Scientific Breakthroughs . . . . .	160
	Specialty Medicine as a Scope of Business . . . . .	160
	Understanding and Exploring the Business of Consumer Electronics . . . . .	160
8.4	Level 3: Leading People for Innovation and Change . . . . .	161
	Creating a Mindset of Change . . . . .	161
	Developing a Transformation Story . . . . .	161
	Overcoming Functional Silos . . . . .	162
	Balancing Scale and Creativity . . . . .	162
	Fail Often to Succeed Sooner . . . . .	162
	Remembering That Drugs Solve Global Problems . . . . .	163
	<b>Glossary . . . . .</b>	<b>165</b>
	<b>Bibliography . . . . .</b>	<b>171</b>
	<b>Index . . . . .</b>	<b>177</b>